Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Shares, par value CHF 0.08 per share
-
Shares outstanding
-
112M
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
54.8M
-
Shares change
-
-1.62M
-
Total reported value, excl. options
-
$77.3M
-
Value change
-
-$2.53M
-
Put/Call ratio
-
1.52
-
Number of buys
-
38
-
Number of sells
-
-33
-
Price
-
$1.41
Significant Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q1 2025
99 filings reported holding ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share as of Q1 2025.
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.8M shares
of 112M outstanding shares and own 49.01% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (15.7M shares), Prosight Management, LP (9.54M shares), ORBIMED ADVISORS LLC (5.97M shares), BlackRock, Inc. (4.91M shares), MORGAN STANLEY (3.02M shares), PLATINUM INVESTMENT MANAGEMENT LTD (2.04M shares), BANK OF AMERICA CORP /DE/ (1.8M shares), GOLDMAN SACHS GROUP INC (1.58M shares), STATE STREET CORP (1.21M shares), and GEODE CAPITAL MANAGEMENT, LLC (970K shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.